抽象
BackgroundThoracentesis using suction is perceived to have increased risk of complications, including pneumothorax and re-expansion pulmonary oedema (REPO). Current guidelines recommend limiting drainage to 1.5 L to avoid REPO. Our purpose was to examine the incidence of complications with symptom-limited drainage of pleural fluid using suction and identify risk factors for REPO.
方法在2018年1月1日至2018年1月31日之间使用我们的机构在我们的机构中进行了症状有限胸腔面的所有成年患者的回顾性队列研究,其中包括总共1044个胸腔。
结果Pleural fluid ≥1.5 L was removed in 19% of the procedures. Thoracentesis was stopped due to chest discomfort (39%), complete drainage of fluid (37%) and persistent cough (13%). Pneumothorax based on chest radiography was detected in 3.98%, but only 0.28% required intervention. The incidence of REPO was 0.08%. The incidence of REPO increased with Eastern Cooperative Oncology Group performance status (ECOG PS) ≥3 compounded with ≥1.5 L (0.04–0.54%; 95% CI 0.13–2.06 L). Thoracentesis in those with ipsilateral mediastinal shift did not increase complications, but less fluid was removed (p<0.01).
Conclusions症状限制胸腔舒适性使用吸力即使具有大量的卷也是安全的。Pneumothorax requiring intervention and REPO are both rare. There were no increased procedural complications in those with ipsilateral mediastinal shift. REPO increased with poor ECOG PS and drainage ≥1.5 L. Symptom-limited drainage using suction without pleural manometry is safe.
抽象
症状限制胸腔舒适性使用吸力即使具有大量的卷也是安全的。气胸需要干预和回购是罕见的。引流≥1.5升,ECOG性能状态3或4增加了repo的风险。https://bit.ly/3ds1hko.
脚注
Author contributions: A.E.S. Sagar and C.A. Jimenez had full access to the all of the data in the study, and take responsibility for the integrity of the data and accuracy of the data analysis, including and especially any adverse effects. M.F. Landaeta, A.M. Adrianza, G.L. Aldana, L. Pozo, A. Armas-Villalba, C.C. Toquica, A.J. Larson, M.R. Vial, F.A. Almeida and M.H. Uzbeck contributed substantially to the study design, data collection, data analysis and interpretation, and the writing of the manuscript. H.B. Grosu, D.E. Ost, G.A. Eapen, R.C. Morice, V.R. Shannon, L. Bashoura, D.D. Balachandran, A. Sheshadri, R.F. Casal and S.A. Faiz contributed to data analysis and interpretation, review and editing of the manuscript.
利益冲突:A.E.S.SAGAR没有披露。
利益冲突:M.F.Landaeta没有什么可以披露的。
利益冲突:上午阿德里安萨无所事事。
利益冲突:G.L.Aldana没有什么可披露的。
利益冲突:L. Pozo无需披露。
Conflict of interest: A. Armas-Villalba has nothing to disclose.
利益冲突:C.C.Toquica没有什么可披露的。
Conflict of interest: A.J. Larson has nothing to disclose.
利益冲突:M.R. Vial没有披露。
利益冲突:H.B.格罗苏没有什么可披露的。
利益冲突:D.E.OST没有什么可以披露的。
利益冲突:G.A.伊埃潘没有披露。
利益冲突:A. Sheshadri没有什么可披露的。
利益冲突:R.C.莫里斯没有任何披露。
利益冲突:V.R.香农无所事事。
利益冲突:L. Bashoura无需披露。
利益冲突:D.D.巴拉邦德尔没有什么可披露的。
Conflict of interest: F.A. Almeida has nothing to disclose.
利益冲突:M.H.Uzbeck没有什么可以披露的。
Conflict of interest: R.F. Casal has nothing to disclose.
利益冲突:S.A.Afiz无需披露。
Conflict of interest: C.A. Jimenez has nothing to disclose.
Support statement: This research is supported in part by the National Institutes of Health through the MD Anderson Cancer Center Support Grant (CA016672).
- 收到2020年1月26日。
- AcceptedMay 27, 2020.
- 复制right ©ERS 2020